These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33057995)

  • 1. KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
    Zhou M; Venkata PP; Viswanadhapalli S; Palacios B; Alejo S; Chen Y; He Y; Pratap UP; Liu J; Zou Y; Lai Z; Suzuki T; Brenner AJ; Tekmal RR; Vadlamudi RK; Sareddy GR
    Breast Cancer Res Treat; 2021 Jan; 185(2):343-357. PubMed ID: 33057995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. USP1-mediated deubiquitination of KDM1A promotes the malignant progression of triple-negative breast cancer.
    Su Y; Du Y; He W
    J Biochem Mol Toxicol; 2024 Oct; 38(10):e23864. PubMed ID: 39318028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDM1A/LSD1 inhibition enhances chemotherapy response in ovarian cancer.
    Chen Y; Johnson JD; Jayamohan S; He Y; Venkata PP; Jamwal D; Alejo S; Zou Y; Lai Z; Viswanadhapalli S; Vadlamudi RK; Kost E; Sareddy GR
    Mol Carcinog; 2024 Oct; 63(10):2026-2039. PubMed ID: 38990091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
    Alejo S; Palacios BE; Venkata PP; He Y; Li W; Johnson JD; Chen Y; Jayamohan S; Pratap UP; Clarke K; Zou Y; Lv Y; Weldon K; Viswanadhapalli S; Lai Z; Ye Z; Chen Y; Gilbert AR; Suzuki T; Tekmal RR; Zhao W; Zheng S; Vadlamudi RK; Brenner AJ; Sareddy GR
    Neuro Oncol; 2023 Jul; 25(7):1249-1261. PubMed ID: 36652263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway.
    Zhang W; Ruan X; Li Y; Zhi J; Hu L; Hou X; Shi X; Wang X; Wang J; Ma W; Gu P; Zheng X; Gao M
    Theranostics; 2022; 12(4):1500-1517. PubMed ID: 35198054
    [No Abstract]   [Full Text] [Related]  

  • 6. KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer.
    Venkata PP; Chen Y; Alejo S; He Y; Palacios BE; Loeffel I; Liu J; Pratap UP; Gray G; Achuthan Pillai SM; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Palakurthi S; Tekmal RR; Vadlamudi RK; Kost E; Sareddy GR
    Cancer Lett; 2022 Jan; 524():219-231. PubMed ID: 34673129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
    De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
    Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
    Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
    Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
    Venkata PP; Jayamohan S; He Y; Alejo S; Johnson JD; Palacios BE; Pratap UP; Chen Y; Liu Z; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Weintraub ST; Palakurthi S; Valente PT; Tekmal RR; Kost ER; Vadlamudi RK; Sareddy GR
    Cancer Lett; 2023 Oct; 575():216383. PubMed ID: 37714256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
    Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide.
    Cámara-Sánchez P; Díaz-Riascos ZV; García-Aranda N; Gener P; Seras-Franzoso J; Giani-Alonso M; Royo M; Vázquez E; Schwartz S; Abasolo I
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor Effect of Demethylzeylasteral (T-96) on Triple-Negative Breast Cancer via LSD1-Mediate Epigenetic Mechanisms.
    Shen Z; Gu Y; Jiang R; Qian H; Li S; Xu L; Gu W; Zuo Y
    Anal Cell Pathol (Amst); 2022; 2022():2522597. PubMed ID: 36276611
    [No Abstract]   [Full Text] [Related]  

  • 17. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
    Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
    Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.
    Sareddy GR; Viswanadhapalli S; Surapaneni P; Suzuki T; Brenner A; Vadlamudi RK
    Oncogene; 2017 Apr; 36(17):2423-2434. PubMed ID: 27893719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells.
    Chu J; Li Y; Fan X; Ma J; Li J; Lu G; Zhang Y; Huang Y; Li W; Huang X; Fu Z; Yin Y; Yuan H
    Cell Physiol Biochem; 2018; 48(2):593-604. PubMed ID: 30021199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.